Reduced Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma – a Phase II StudyCarl Shultz, Lauren Veltri, Steven Rollins et al.|Transplantation and Cellular Therapy|2021Cited by 0